CHF
CONCLUSIONS: Six-month       intermittent low-dose dobutamine administration was well tolerated by patients       with severe CHF; it did not improve the functional status and did not       significantly increase the mortality rate as found with higher dobutamine doses       in other studies.
CONCLUSIONS: Six-month       intermittent low-dose dobutamine administration was well tolerated by  @OBJECT$         @PREDICAT$  severe  @SUBJECT$ ; it did not improve the functional status and did not       significantly increase the mortality rate as found with higher dobutamine doses       in other studies.